ARTICLE | Company News
Genentech, Sequitur deal
November 25, 2002 8:00 AM UTC
Sequitur will provide antisense/RNAi compounds and methods to DNA for target validation studies. Sequitur said antisense/RNAi can help determine gene function and validate small molecule drug targets ...